Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients
Part of paid clinical trials in Oxnard, California.
- Sponsor
- Geriatric Oncology Consortium
- Study ID
- NCT00120198
- Phase
- PHASE2
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 65 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- CDOP plus rituximab — DRUG
Study Details
Currently there is no one standard of care for older patients with Non-Hodgkin's Lymphoma (NHL). The study will examine the tolerability and feasibility to the combination of Cyclophosphamide, Pegylated Liposomal Doxorubicin, Vincristine, Prednisone (CDOP) plus Rituximab.
Key Dates
- Start date
- Mar 31, 2005
- Status verified
- Nov 2007
- Completion
- Sep 30, 2006
Study Design
- Enrollment
- 50 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
To evaluate the feasibility and tolerability of CDOP plus rituximab in elderly patients with previously untreated NHL.
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| - | Oxnard | California | 93030 | - |
| - | Washington D.C. | District of Columbia | 20007 | - |
| - | Inverness | Florida | 34452 | - |
| - | Lecanto | Florida | 34461 | - |
| - | Belleville | New Jersey | 07109 | - |
Related Studies
- ID Of Prognostic Factors In Mycosis Fungoides/Sezary SyndromeRecruiting · Stanford University · Duarte, California
- T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)PHASE1/PHASE2 · Recruiting · Estrella Biopharma, Inc. · Sacramento, California
- Establishing a Tumor Bank in Families With Multiple Lymphoproliferative MalignanciesRecruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALEPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas